Fulcrum Therapeutics (NASDAQ:FULC) focuses on developing transformative medicines to improve the lives of patients with genetically defined rare diseases. Dedicated to tackling conditions that have limited treatment options, the company leverages advanced scientific research to identify and address the root causes of these diseases. Their pipeline includes projects targeting sickle cell disease and facioscapulohumeral muscular dystrophy, among others. With a steadfast commitment, Fulcrum aims to deliver groundbreaking therapies that can offer renewed hope and tangible benefits to those they serve.